Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

Inclusion Criteria: * Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology \[ACR\] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced Magnetic Resonance Mammography (MRM) prior to surgery of the breast. * if female, a digital XRM is required if any of the following criteria is met: * a. patient is younger than 50 years; * b. patient has heterogeneously or extremely dense breasts; * c. is not post-menopausal (post-menopause defined as at least 12 months prior to inclusion without menstruation). * if female of childbearing potential, MRM should be performed on the 7-14th day of the menstrual cycle. * has an estimated glomerular filtration rate (eGFR) value \>/= 60 mL/min/1.73m\^2 derived from a serum creatinine result within 2 weeks prior to study enrollment. Exclusion Criteria: * is a female patient who is pregnant or lactating * has any contraindication to the MRM examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents. * has received any contrast agent within 24 hours prior to the study MRM, or is scheduled to receive any contrast agent within 24 hours after the study MRM. * has severe cardiovascular disease (e.g., known long QT syndrome, acute myocardial infarction \[\< 14 days\], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (\< 48 hours)). * has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate \< 60 mL/min/1.73m\^2). * has received chemotherapy or hormonal therapy for breast cancer within 6 months. * has received hormone replacement therapy within 4 weeks prior to study drug administration. * is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application * has prior excisional biopsy or breast surgery less than 6 months before enrollment and between XRM and study MRM